|
|
1212 Terra Bella Avenue
Mountain View, CA 94043 USA
phone:(650) 940-4700
fax:(650) 940-4710
|
|
| Symbol |
IRIX |
| Exchange |
Nasdaq |
| Founded |
1989 |
| Employees |
114 |
|
|
| www.iridex.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Laser systems to treat eye diseases |
|
| Management |
| Theodore A. Boutacoff, President and CEO; James H. Mackaness, Chief Financial Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| laser, ophthalmology, dermatology, blindness, diabetes, blood sugar, diabetic, metabolic, photocoagulation, acquisitions, organic growth, turnaround, profitability, Iridex, macular degeneration, eye surgery. |
|
|
|
| Description |
|
IRIDEX develops, manufactures and markets medical devices, including semiconductor-based lasers and consumable products used to treat eye diseases in ophthalmology and skin conditions in dermatology. The laser system includes a console, which generates the laser energy and a number of interchangeable peripheral delivery devices, including disposable delivery devices for use in specific clinical applications. The company's technologies are currently resident in more than 10,000 ophthalmology practices throughout the world. Those technologies serve to treat a wide range of conditions including age-related macular degeneration, diabetic retinopathy and glaucoma in the eye, as well as skin rejuvenation, vascular lesions and pigmented lesions of the skin. |
|
| Products / Services |
Lasers ands a wide range of compatible delivery devices including single use disposable probes to a wide range of treat eye diseases and skin conditions.
|
|
| Technology / Differentiation |
| The company has developed and is now marketing an advanced micro-pulse photocoagulation laser that can effectively treat age-related ophthalmic conditions without the damage to tissue that resulted from currently standard technologies. This new technology may be the catalyst for physicians to migrate away from the long term use of drug intervention and increase the replacement cycle for more than 25,000 photocoagulation lasers currently in use. |
|
| Market / Customers |
The company's products are sold in the United States predominantly through a direct sales force and internationally through 68 independent distributors into more than 100 countries.
|
|
| Competitors / Substitutes / Alternatives |
Lumenis Ltd., Carl Zeiss Meditec AG, Alcon Inc., Quantel, Laserex, Nidek, Inc, Novartis, Eyetech
|
|
| Strategy |
Now profitable and generating cash, the company plans to accelerate growth through a dual pronged strategy of internal growth and acquisition. The company plans the development or purchase of consumable product technologies at a rate of one or more per year and the acquisition of additional diagnostic and therapeutic technologies for ophthalmology on an opportunistic basis. Iridex? plans for the greater penetration of its micro-pulse photocoagulation laser are also intended to grow the market as well as accelerate the capital equipment replacement cycle ? resulting in strong organic growth in coming periods and years.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members